Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.
Smith+Nephew (SNN) Introduces Real Intelligence & CORI System
by Zacks Equity Research
Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.
Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care
by Zacks Equity Research
Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.
Here's Why You Should Hold on to Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.
3 Reasons Growth Investors Will Love Omnicell (OMCL)
by Zacks Equity Research
Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Add Omnicell (OMCL) To Your Portfolio
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.
Walgreens (WBA) to Offer COVID-19 Vaccine Booster Shots
by Zacks Equity Research
Individuals aged 18 years or older are eligible to avail Pfizer, Moderna or Johnson & Johnson COVID-19 vaccine boosters from Walgreens' (WBA) stores.
NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJR
Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Should SPDRSP6 SC (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Should SPDRSP6 SC (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed
by Zacks Equity Research
Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.
QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.
Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.
Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.
NXGN or OMCL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH